A review of pharmacogenetics of adverse drug reactions in elderly people

Drug Safety

Volumn 35, Issue SUPPL. 1, 2012, Pages 3-20

  Cardelli, Maurizio ^a   Marchegiani, Francesca ^a   Corsonello, Andrea ^a   Lattanzio, Fabrizia ^a   Provinciali, Mauro ^a  

^a INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BIOLOGICAL MARKER; CARRIER PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DONEPEZIL; DRUG METABOLIZING ENZYME; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; RIVASTIGMINE; TAMOXIFEN; UNINDEXED DRUG; WARFARIN;

ADVERSE DRUG REACTION; AGED; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; BLEEDING; BREAST CANCER; CAUSE OF DEATH; COPY NUMBER VARIATION; DIAGNOSTIC KIT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HIGH RISK POPULATION; HUMAN; IATROGENIC DISEASE; INDEL MUTATION; LOW DRUG DOSE; MEDICATION ERROR; MEDLINE; MYALGIA; MYOPATHY; PHARMACOGENETICS; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SELF MEDICATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICING DEFECT; TREATMENT REFUSAL;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG TOXICITY; GLUCURONOSYLTRANSFERASE; HUMANS; METHYLTRANSFERASES; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84873864620     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/BF03319099     Document Type: Review

References (141)

1. McLean AJ, Le Couter DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84
2. Atkin PA, Veitch PC, Veitch EM, et al. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging 1999; 14 (2): 141-52
3. Obreli Neto PR, Nobili A, de Lyra Júnior DP, et al. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. J Pharm Pharmaceut Sci 2012; 15 (2): 332-43 (www.cspsCanada.org)
4. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004 Feb; 57 (2): 121-6
5. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002 Dec; 50 (12): 1962-8
6. Ruiter R, Visser LE, Rodenburg EM, et al. Adverse drug reaction-related hospitalizations in persons aged 55 years and over: a population-based study in the Netherlands. Drugs Aging 2012 Mar; 29 (3): 225-32
7. Tangiisuran B, Davies JG, Wright JE, et al. Adverse drug reactions in a population of hospitalized very elderly patients. Drugs Aging 2012 Aug; 29 (8): 669-79
8. Hofer-Dueckelmann C, Prinz E, Beindl W, et al. Adverse drug reactions (ADRs) associated with hospital admissions-elderly female patients are at highest risk. Int J Clin Pharmacol Ther 2011 Oct; 49 (10): 577-86
9. Conforti A, Costantini D, Zanetti F, et al. Adverse drug reactions in older patients: an Italian observational prospective hospital study. Drug Healthc Patient Saf 2012; 4: 75-80
10. Scott IA, Gray LC, Martin JH, et al. Effects of a drug minimization guide on prescribing intentions in elderly persons with polypharmacy. Drugs Aging 2012; 29: 659-67
11. Beutler E, Dern RJ, Flanagan CL, et al. The hemolytic effect of primaquine. VII. Biochemical studies of drugsensitive erythrocytes. J Lab Clin Med 1955; 45: 286-95
12. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6: 904-16
13. American Association of Pharmaceutical Scientists. Pharmacogenomics (PGx) Focus Group. https://www.aapsj.org/inside/focus-groups/PGX/index.asp.[Accessed 2011Sep 9]
14. Note for guidance on definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. EMEA/CHMP/ICH/437986/2006. November 2007 from the ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002880.pdf
15. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286 (5439): 487-91
16. Pirazzoli A, Recchia G. Pharmacogenetics and pharmacogenomics: are they still promising? Pharmacol Res 2004 Apr; 49 (4): 357-61
17. Lee KC, Ma JD, Kuo GM. Pharmacogenomics: bridgingthe gap between science and practice. J Am Pharm Assoc (2003) 2010 Jan-Feb; 50 (1): e1-14; quiz e15-17
18. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011 Jun; 12 (5): 487-97
19. Goodman LS, Gilman A, Brunton LL, et al. Goodman & Gilman's thepharmacological basis of therapeutics. 11th ed. McGraw-Hill, New York City, U.S. 2006
20. Singh D, Kashyap A, Pandey RV, et al. Novel advances in cytochrome P450research. Drug Discov Today 2011 Sep; 16 (17-18): 793-9
21. Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, includingnomenclature recommendations for genes, pseudogenes and alternative-splicevariants. Pharmacogenetics 2004 Jan; 14 (1): 1-18
22. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence ofcytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007 Dec; 116 (3): 496-526
23. Cacabelos R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diagn 2009 Sep; 9 (6): 567-611
24. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006 Jan; 10 (1): iii-iv, ix-xi, 1-160
25. Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil inpatients with Alzheimer disease. Neurology 2009 Sep; 73 (10): 761-7
26. Seripa D, Bizzarro A, Pilotto A, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics 2011 Apr; 21 (4): 225-30
27. Chianella C, Gragnaniello D, Maisano Delser P, et al. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 2011 Nov; 67 (11): 1147-57
28. Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs 2010 Feb; 24 (2): 163-76
29. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad SciUSA1993 Dec; 90 (24): 11825-9
30. Kleine-Brueggeney M, Musshoff F, Stuber F, et al. Pharmacogenetics in palliative care. Forensic Sci Int 2010 Dec; 203 (1-3): 63-70
31. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Investig 2003; 33 Suppl. 2: 23-30
32. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16
33. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999 Feb; 353 (9154): 717-9
34. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004 Mar; 75 (3): 204-12
35. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX,and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004 Apr; 103 (7): 2630-5
36. Rane A, Lindh JD. Pharmacogenetics of anticoagulants. Hum Genomics Proteomics 2010 Sep; 754919
37. Seripa D, Paroni G, Urbano M, et al. Pharmacogenetics in older people: what we know and what we need to know. J Nephrol 2012; 25 Suppl. 19: 38-47
38. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulationrelated outcomes during warfarin therapy. JAMA 2002 Apr; 287 (13): 1690-8
39. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113 (4): 784-92
40. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352 (22): 2285-93
41. Millican EA, Lenzini PA, Milligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007 Sep; 110 (5): 1511-5
42. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedicpatients. J Thromb Haemost 2008 Oct; 6 (10): 1655-62
43. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360 (8): 753-64
44. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010; 11 (4): 493-6
45. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010; 87 (1): 57-64
46. Moreau C, Pautas E, Gouin-Thibault I, et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost 2011; 9 (4): 711-8
47. Kovac MK, Rakicevic LB, Kusic-Tisma JS, et al. Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation. J Thromb Thrombolysis 2012 Jul 6. [Epub ahead of print]
48. Pilotto A, Franceschi M, Vitale DF, et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. Aliment Pharmacol Ther 2005; 22 (2): 147-55
49. Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133 (2): 465-71
50. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200
51. Klotz U. Clinical impact of CYP2C19 polymorphism on theaction of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44 (7): 297-302
52. Singh G, Saxena N, Aggarwal A, et al. Cytochrome p450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 2007; 34: 731-3
53. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58
54. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006 Jan; 79 (1): 103-13
55. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002 Oct; 72 (4): 453-60
56. Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-73
57. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19 (12): 911-27
58. Ishizawa Y, Yasui-Furukori N, Takahata T, et al. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 2005; 44 (11): 1179-89
59. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304 (16): 1821-30
60. Fuster V, Sweeny JM. Clopidogrel and the reducedfunction CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. JAMA 2010; 304 (16): 1839-40
61. PriceMJ,Murray SS, AngiolilloDJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012 May; 59 (22): 1928-37
62. Lewis JP, Shuldiner AR. Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction? Circ Cardiovasc Genet 2012 Apr; 5 (2): 153-5
63. Kreutz RP, Nystrom P, Kreutz Y, et al. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol 2012; 4: 13-20
64. Reny JL, Combescure C, Daali Y, et al., PON1 Meta-Analysis Group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and metaanalysis. J Thromb Haemost 2012 Jul; 10 (7): 1242-51
65. Lescai F, Marchegiani F, Franceschi C. PON1 is a longevity gene: results of a meta-analysis. Ageing Res Rev 2009 Oct; 8 (4): 277-84
66. Marchegiani F, Spazzafumo L, Provinciali M, et al. Paraoxonase2 C311S polymorphism and low levels of HDL contribute to a higher mortality risk after acute myocardial infarction in elderly patients. Mol Genet Metab 2009 Nov; 98 (3): 314-8
67. Marchegiani F, Spazzafumo L, Cardelli M, et al. Paraoxonase- 1 55 LL genotype is associated with no STelevation myocardial infarction and with high levels of myoglobin. J Lipids 2012; 2012: 601796
68. Marchegiani F, Marra M, Olivieri F, et al. Paraoxonase 1: genetics and activities during aging. Rejuvenation Res 2008 Feb; 11 (1): 113-27
69. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376-85
70. Wilke RA, Ramsey LB, Johnson SG, et al., Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012 Jul; 92 (1): 112-7
71. Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002 Dec; 72 (6): 685-91
72. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291 (23): 2821-7
73. Medina MW, Gao F, Ruan W, et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzymeA reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008; 118 (4): 355-62
74. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic druguptake. Pharmacol Rev 2011 Mar; 63 (1): 157-81
75. Akao H, Polisecki E, Kajinami K, et al. Genetic variationat the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis 2012; 220 (2): 413-7
76. SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-inducedmyopathy - a genomewide study. N Engl JMed 2008 Aug; 359 (8): 789-99
77. Voora D, Shah SH, Spasojevic I, et al. TheSLCO1B1&z.ast;l5 genetic variant is associated with statin-induced side effects. J AmColl Cardiol 2009 Oct; 54 (17): 1609-16
78. Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associatedwith simvastatin and atorvastatin. Pharmacogenomics J 2012 Jun; 12 (3): 233-7
79. Unützer J. Clinical practice. Late-life depression. N Engl J Med 2007; 357 (22): 2269-75
80. Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004 Aug; 174 (4): 525-9
81. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996 Jun; 66 (6): 2621-4
82. Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol 2008 Dec; 4 (12): 1465-78
83. Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006 May; 78 (5): 815-26
84. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 Nov; 23 (5): 587-90
85. Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008 Mar; 33 (2): 123-30
86. Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch GenPsychiatry 2007 Jul; 64 (7): 783-92
87. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009 Apr; 150B (3): 341-51
88. Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011 Sep; 12 (9): 1321-36
89. Scartozzi M, Loretelli C, Berardi R, et al. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Dig Liver Dis 2012; 44 (1): 74-9
90. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010 Feb; 125 (2 Suppl. 2): S3-23
91. Naumova E, Ivanova M, Pawelec G. Immunogenetics of ageing. Int J Immunogenet 2011; 38 (5): 373-81
92. Nedorost ST, Stevens SR. Diagnosis and treatment of allergic skin disorders in the elderly. Drugs Aging 2001; 18 (11): 827-35
93. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486
94. Man CB, Kwan P, Baum L, et al. Association between HLA-B&z.ast;1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-8
95. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with the HLA-B&z.ast;1502 allele in a Thai population. Epilepsia 2008; 49: 2087-91
96. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B&z.ast;1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579-82
97. Kaniwa N, Saito Y, Aihara M, et al. JSAR research group HLA -B locus in Japaneses patients treated with antiepileptic or antimicrobial agents. Pharmacogenomics 2008; 9: 1617-22
98. Lonjou C, Thomas L, Borot N, et al. RegiSCAR Group A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-8
99. Kuehn BM. FDA: epilepsy drugs may carry skin risks for Asians. JAMA 2008; 300 (24): 2845
100. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16 (4): 297-306
101. McCormackM, Alfirevic A, Bourgeois S, et al. HLA-A&z.ast;3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364 (12): 1134-43
102. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A&z.ast;3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20 (5): 1034-41
103. Kaniwa N, Saito Y, Aihara M, et al. HLA-B&z.ast;1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010; 51 (12): 2461-5
104. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepineinduced cutaneous adverse reactions. Epilepsia 2010; 51 (2): 297-300
105. Hung SI, Chung WH, Liou LB, et al. HLA-B&z.ast;5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-9
106. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B&z.ast;5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-9
107. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B&z.ast;5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32
108. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2
109. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-11
110. Mallal S, Phillips E, Carosi G, et al. PREDICT-1 Study Team HLA-B&z.ast;5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79
111. Daly AK, Donaldson PT, Bhatnagar P, et al., DILIGEN Study; International SAE Consortium. HLA-B&z.ast;5701 genotype is a major determinant of drug-induced liver injury due toflucloxacillin. Nat Genet 2009 Jul; 41 (7): 816-9
112. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010 Aug; 42 (8): 711-4
113. Alfirevic A, Gonzalez-Galarza F, Bell C, et al. In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med 2012 Jun; 4 (6): 51
114. Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics 2010 Apr; 4 (4): 238-49
115. Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008; 9: 703-15
116. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy 2008; 28: 755-68
117. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyl-transferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106: 97-132
118. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011 Feb; 32 (2): 72-81
119. Zhou S. Clinical pharmacogenomics of thiopurine S-methyl-transferase. Curr Clin Pharmacol 2006 Jan; 1 (1): 119-28
120. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008 Aug; 64 (8): 753-67
121. Aliabadi AZ, Zuckermann AO, Grimm M. Immunosuppressive therapy in older cardiac transplant patients. Drugs Aging 2007; 24 (11): 913-32
122. Mishra PJ, Bertino Jr. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 2009 Mar; 10 (3): 399-416
123. Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics. 2007 Dec; 8 (12): 1625-7
124. Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A. 2007 Aug 14; 104 (33): 13513-8
125. Mishra PJ, Mishra PJ, Banerjee D, et al. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 2008 Apr 1; 7 (7): 853-8
126. Garofalo M, Condorelli G, Croce CM. MicroRNAs in diseases and drug response. Curr Opin Pharmacol 2008 Oct; 8 (5): 661-7
127. Wu Y, Xiao Y, Ding X, et al. A miR-200b/200c/429-binding site polymorphism in the 30 untranslated region of the AP-2a gene is associated with cisplatin resistance. PLoS ONE 2011; 6 (12): e29043
128. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010; 11: 241-6
129. Paula Careta F, Paneto GG. Recent patents on highthroughput single nucleotide polimorphism (SNP)genotyping methods. Recent Pat DNA Gene Seg 2012; 6: 122-6
130. Fernandez-Rozadilla C, Cazier JB, Moreno V, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J 2012 Feb 7 (Epub ahead of print)
131. Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxelinduced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012 Sep 15; 18 (18): 5099-109
132. Clark SL, Adkins DE, Aberg K, et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR&z.ast;D. Psychol Med 2012 Jun; 42 (6): 1151-62
133. Trompet S, de Craen AJ, Postmus I, et al. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Med Genet 2011 Oct 6; 12: 131
134. Takeuchi F, McGinnis R, Bourgeois S, et al. A genomewide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009 Mar; 5 (3): e1000433
135. Yang JJ, Plenge RM. Genomic technology applied to pharmacological traits. JAMA 2011 Aug 10; 306 (6): 652-3
136. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010 Mar 18; 464 (7287): 405-8
137. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011 Feb; 43 (2): 117-20
138. Nelson MR, Bacanu SA, Mosteller M, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009 Feb; 9 (1): 23-33
139. Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clinical Pharmacology & Therapeutics 2012; 92: 235-42
140. Ng PC, Murray SS, Levy S, et al. An agenda for personalized medicine. Nature 2009 Oct 8; 461 (7265): 724-6
141. Tzvetkov M, von Ahsen N. Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. Pathology 2012 Feb; 44 (2): 166-80